fa مقایسه سطح سرمی کارسینو امبریونیک آنتی ژن، پرولاکتین و مالون دی آلدهید در بیماران مبتلا به سرطان پستان و افراد سالم در اصفهان بيوشيمي بالینی Biochemistry پژوهشي Research <p class="MsoNormal" style="margin: 0cm 0cm 10pt text-align: justify line-height: normal" dir="rtl"><b><span lang="FA" style="font-family: ">زمینه و هدف:</span></b><span lang="FA" style="font-family: "> سرطان پستان یکی از شایع‌ترین سرطان‌ها در بین زنان است. هدف از این مطالعه مقایسه سطح سرمی نشانگر توموری (</span><span style="font-family: " dir="ltr">Carcinoembryonic antigen</span><span dir="rtl"></span><span dir="rtl"></span><span lang="FA" style="font-family: "><span dir="rtl"></span><span dir="rtl"></span>) </span><span style="font-family: " dir="ltr">CEA</span><span dir="rtl"></span><span dir="rtl"></span><span lang="FA" style="font-family: "><span dir="rtl"></span><span dir="rtl"></span>، پرولاکتین و نشانگر اکسیداتیو مالون دی آلدهید (</span><span style="font-family: " dir="ltr">MDA</span><span dir="rtl"></span><span dir="rtl"></span><span lang="FA" style="font-family: "><span dir="rtl"></span><span dir="rtl"></span>)</span><span dir="ltr"></span><span dir="ltr"></span><span lang="FA" style="font-family: " dir="ltr"><span dir="ltr"></span><span dir="ltr"></span> </span><span lang="FA" style="font-family: ">در دو گروه سالم و مبتلا به سرطان پستان است.<o:p /></span></p><font face="Times New Roman" size="3"></font><p class="MsoNormal" style="margin: 0cm 0cm 10pt text-align: justify line-height: normal" dir="rtl"><b><span lang="FA" style="font-family: ">مواد و روش‌ها:</span></b><span lang="FA" style="font-family: "> این مطالعه موردی </span><span lang="FA" style="font-family: ">–</span><span lang="FA" style="font-family: "> شاهدی بر روی مراجعه کنندگان به بیمارستان سیدالشهداء اصفهان انجام شد. این بررسی بر روی 44</span><span dir="ltr"></span><span dir="ltr"></span><span lang="FA" style="font-family: " dir="ltr"><span dir="ltr"></span><span dir="ltr"></span> </span><span lang="FA" style="font-family: ">زن مبتلا به سرطان پستان تحت درمان و 44 زن سالم انجام شد. اندازه‌گیری </span><span style="font-family: " dir="ltr">CEA</span><span dir="rtl"></span><span dir="rtl"></span><span lang="FA" style="font-family: "><span dir="rtl"></span><span dir="rtl"></span> و پرولاکتین به روش </span><span style="font-family: " dir="ltr">ELISA</span><span dir="rtl"></span><span dir="rtl"></span><span lang="FA" style="font-family: "><span dir="rtl"></span><span dir="rtl"></span> و اندازه‌گیری </span><span style="font-family: " dir="ltr">MDA</span><span dir="rtl"></span><span dir="rtl"></span><span lang="FA" style="font-family: "><span dir="rtl"></span><span dir="rtl"></span> بر اساس واکنش با تیوباربیتوریک اسید انجام گرفت.<font size="2"><font face="B Nazanin"><span style="mso-spacerun: yes"> </span><o:p /></font></font></span></p><font face="Times New Roman" size="3"></font><p class="MsoNormal" style="margin: 0cm 0cm 10pt text-align: justify line-height: normal" dir="rtl"><b><span lang="FA" style="font-family: ">نتایج:</span></b><span lang="FA" style="font-family: "> میانگین </span><span style="font-family: " dir="ltr">CEA</span><span dir="rtl"></span><span dir="rtl"></span><span style="font-family: "><span dir="rtl"></span><span dir="rtl"></span> <span lang="FA"><font face="B Nazanin" size="2">در بیماران مبتلا به سرطان پستان (</font></span></span><span style="font-family: " dir="ltr">ng/ml</span><span dir="rtl"></span><span dir="rtl"></span><span lang="FA" style="font-family: "><span dir="rtl"></span><span dir="rtl"></span> 78/1 </span><span dir="ltr"></span><span dir="ltr"></span><span style="font-family: " dir="ltr"><span dir="ltr"></span><span dir="ltr"></span>±</span><span dir="rtl"></span><span dir="rtl"></span><span lang="FA" style="font-family: "><span dir="rtl"></span><span dir="rtl"></span> 175/2) به طور معنا داری بیشتر از افراد گروه سالم بود (</span><span style="font-family: " dir="ltr">ng/ml</span><span dir="rtl"></span><span dir="rtl"></span><span lang="FA" style="font-family: "><span dir="rtl"></span><span dir="rtl"></span> 85/0 </span><span dir="ltr"></span><span dir="ltr"></span><span style="font-family: " dir="ltr"><span dir="ltr"></span><span dir="ltr"></span>±</span><span dir="rtl"></span><span dir="rtl"></span><span lang="FA" style="font-family: "><span dir="rtl"></span><span dir="rtl"></span> 161/1) (001/0</span><span style="font-family: " dir="ltr">P < </span><span dir="rtl"></span><span dir="rtl"></span><span lang="FA" style="font-family: "><span dir="rtl"></span><span dir="rtl"></span>)، میانگین پرولاکتین در دو گروه بیمار و سالم با هم تفاوت معناداری نداشت و میانگین غلظت مالون دی آلدهید در مبتلایان به سرطان پستان (</span><span dir="ltr"></span><span dir="ltr"></span><span style="font-family: " dir="ltr"><span dir="ltr"></span><span dir="ltr"></span> mol/dl</span><span lang="FA" style="font-family: ">µ</span><span lang="FA" style="font-family: "> 37/0 </span><span dir="ltr"></span><span dir="ltr"></span><span style="font-family: " dir="ltr"><span dir="ltr"></span><span dir="ltr"></span>±</span><span dir="rtl"></span><span dir="rtl"></span><span lang="FA" style="font-family: "><span dir="rtl"></span><span dir="rtl"></span> 44/1) به طور معناداری بیشتر از افراد سالم بود (</span><span style="font-family: " dir="ltr">mol/dl</span><span dir="rtl"></span><span dir="rtl"></span><span style="font-family: "><span dir="rtl"></span><span dir="rtl"></span> </span><span lang="FA" style="font-family: ">µ</span><span dir="ltr"></span><span dir="ltr"></span><span lang="FA" style="font-family: " dir="ltr"><span dir="ltr"></span><span dir="ltr"></span> </span><span dir="rtl"></span><span dir="rtl"></span><span lang="FA" style="font-family: "><span dir="rtl"></span><span dir="rtl"></span>25 /0 </span><span dir="ltr"></span><span dir="ltr"></span><span style="font-family: " dir="ltr"><span dir="ltr"></span><span dir="ltr"></span>±</span><span dir="rtl"></span><span dir="rtl"></span><span lang="FA" style="font-family: "><span dir="rtl"></span><span dir="rtl"></span> 27/1) (01/0</span><span style="font-family: " dir="ltr">P < </span><span dir="rtl"></span><span dir="rtl"></span><span lang="FA" style="font-family: "><span dir="rtl"></span><span dir="rtl"></span>).<font size="2"><font face="B Nazanin"><span style="mso-spacerun: yes"> </span><o:p /></font></font></span></p><font face="Times New Roman" size="3"></font><p class="MsoNormal" style="margin: 0cm 0cm 10pt text-align: justify line-height: normal" dir="rtl"><b><span lang="FA" style="font-family: ">نتیجه‌گیری:</span></b><span lang="FA" style="font-family: "> از </span><span dir="ltr"></span><span dir="ltr"></span><span lang="FA" style="font-family: " dir="ltr"><span dir="ltr"></span><span dir="ltr"></span><span style="mso-spacerun: yes"><font face="Times New Roman" size="2"> </font></span></span><span style="font-family: " dir="ltr">CEA</span><span lang="FA" style="font-family: ">می‌توان به عنوان یک سرم مارکر با ارزش جهت موثر بودن روند درمان و هم چنین تشخیص سرطان پستان متاستاتیک استفاده کرد. همچنین نقش پراکسیداسیون</span><span dir="ltr"></span><span dir="ltr"></span><span lang="FA" style="font-family: " dir="ltr"><span dir="ltr"></span><span dir="ltr"></span> </span><span lang="FA" style="font-family: ">لیپیدی</span><span dir="ltr"></span><span dir="ltr"></span><span lang="FA" style="font-family: " dir="ltr"><span dir="ltr"></span><span dir="ltr"></span> </span><span lang="FA" style="font-family: ">به</span><span dir="ltr"></span><span dir="ltr"></span><span lang="FA" style="font-family: " dir="ltr"><span dir="ltr"></span><span dir="ltr"></span> </span><span lang="FA" style="font-family: ">عنوان یک</span><span dir="ltr"></span><span dir="ltr"></span><span lang="FA" style="font-family: " dir="ltr"><span dir="ltr"></span><span dir="ltr"></span> </span><span lang="FA" style="font-family: ">فرآیند</span><span dir="ltr"></span><span dir="ltr"></span><span lang="FA" style="font-family: " dir="ltr"><span dir="ltr"></span><span dir="ltr"></span> </span><span lang="FA" style="font-family: ">دخیل</span><span dir="ltr"></span><span dir="ltr"></span><span lang="FA" style="font-family: " dir="ltr"><span dir="ltr"></span><span dir="ltr"></span> </span><span lang="FA" style="font-family: ">در</span><span dir="ltr"></span><span dir="ltr"></span><span lang="FA" style="font-family: " dir="ltr"><span dir="ltr"></span><span dir="ltr"></span> </span><span lang="FA" style="font-family: ">ایجاد</span><span dir="ltr"></span><span dir="ltr"></span><span lang="FA" style="font-family: " dir="ltr"><span dir="ltr"></span><span dir="ltr"></span> </span><span lang="FA" style="font-family: ">سرطان</span><span dir="ltr"></span><span dir="ltr"></span><span lang="FA" style="font-family: " dir="ltr"><span dir="ltr"></span><span dir="ltr"></span> </span><span lang="FA" style="font-family: ">پستان تایید شد.<o:p /></span></p><font face="Times New Roman" size="3"></font> <font face="Times New Roman" size="3"> </font><font face="Times New Roman" size="3"><b><i><span style="color: black font-family: ">Background</span></i></b><span dir="rtl"></span><span dir="rtl"></span><b><i><span style="color: black font-family: " dir="rtl"><span dir="rtl"></span><span dir="rtl"></span> </span></i></b><b><i><span lang="FA" style="color: black font-family: " dir="rtl">& </span></i></b><b><i><span style="color: black font-family: ">Objective:</span></i></b><span style="color: black font-family: "> One of the most prevalent types of cancer among women is breast cancer. The objective of this study is to compare the serum level of tumor marker of Carcinoembryonic Antigen (CEA), Prolactin, and oxidative marker Malondialdehyde (MDA) in patients with breast cancer and in control groups</span><span dir="rtl"></span><span dir="rtl"></span><span lang="FA" style="color: black font-family: " dir="rtl"><span dir="rtl"></span><span dir="rtl"></span>.<o:p /></span> <p class="MsoNormal" style="margin: 0cm 0cm 0pt text-align: justify line-height: normal unicode-bidi: embed direction: ltr"><span style="color: black font-family: "><!--stripped--><font size="2"> </font><!--stripped--></span><b><i><span style="color: black font-family: ">Materials </span></i></b><span dir="rtl"></span><span dir="rtl"></span><b><i><span lang="FA" style="color: black font-family: " dir="rtl"><span dir="rtl"></span><span dir="rtl"></span>&</span></i></b><span dir="ltr"></span><span dir="ltr"></span><b><i><span style="color: black font-family: "><span dir="ltr"></span><span dir="ltr"></span> Methods:</span></i></b><span style="color: black font-family: "> This case control study was carried out on the people who went to Seyedo Shohada Hospital in Isfahan. The experimental group was composed of 44 patients with breast cancer who were under treatment and the control group consisted of 44 healthy people. The amount of CEA and Prolactin was measured via ELISA, while the measurement of MDA was made manually and on the basis of reaction to Thiobarbituric acid</span><span dir="rtl"></span><span dir="rtl"></span><span lang="FA" style="color: black font-family: " dir="rtl"><span dir="rtl"></span><span dir="rtl"></span>.</span></p> <p class="MsoNormal" style="margin: 0cm 0cm 0pt text-align: justify line-height: normal unicode-bidi: embed direction: ltr"><b><i><span style="color: black font-family: ">Results:</span></i></b><span style="color: black font-family: "> The results of the current study indicated that the mean concentration of CEA in patients with breast cancer (2.175 ± 1.78ng/ml) was significantly greater than that of healthy people (1.161 ± 0.85ng/ml) (P < 0.001). The mean concentration of prolactin in patients with breast cancer and in healthy people were not significantly different, and the mean concentration of MDA of the patients with breast cancer (1.44 ±<font face="Times New Roman"><font size="2"><span style="mso-spacerun: yes"> </span>0.37</font></font></span><span lang="FA" style="color: black font-family: " dir="rtl">µ</span><span lang="FA" style="color: black font-family: " dir="rtl"> </span><span dir="ltr"></span><span dir="ltr"></span><span style="color: black font-family: "><span dir="ltr"></span><span dir="ltr"></span><font face="Times New Roman"><font size="2"><span style="mso-spacerun: yes"> </span>mol/dl ) was significantly greater than that of the healthy people(1.27 ±<span style="mso-spacerun: yes"> </span>0.25</font></font></span><span lang="FA" style="color: black font-family: " dir="rtl">µ</span><span lang="FA" style="color: black font-family: " dir="rtl"> </span><span dir="ltr"></span><span dir="ltr"></span><span style="color: black font-family: "><span dir="ltr"></span><span dir="ltr"></span><font size="2"><font face="Times New Roman"><span style="mso-spacerun: yes"> </span>mol/dl ) (P < 0.01</font></font></span><span dir="rtl"></span><span dir="rtl"></span><span lang="FA" style="color: black font-family: " dir="rtl"><span dir="rtl"></span><span dir="rtl"></span>.( </span></p> <p class="MsoNormal" style="margin: 0cm 0cm 0pt text-align: justify line-height: normal unicode-bidi: embed direction: ltr"><b><i><span style="color: black font-family: ">Conclusion:</span></i></b><span style="color: black font-family: "> CEA can be used as a valuable serum marker in the efficacy of the treatment procedure as well as the diagnosis of metastatic breast cancer. Moreover, the role of lipid peroxidation as an effective process in the formation of breast cancer was confirmed</span><span dir="rtl"></span><span dir="rtl"></span><span lang="FA" style="color: black font-family: " dir="rtl"><span dir="rtl"></span><span dir="rtl"></span>.</span></p> </font> سرطان پستان, CEA, پرولاکتین, مالون دی آلدهید Breast cancer, CEA, Prolactin, Malondialdehyde 362 370 http://jabs.fums.ac.ir/browse.php?a_code=A-10-173-1&slc_lang=fa&sid=1 Sana Taghiyar ثنا تقی یار 10031947532846005668 10031947532846005668 No Department of Biochemistry, Islamic Azad University, Fars Science and Research Branch, Fars, Iran. گروه بیوشیمی، دانشگاه آزاد اسلامی، واحد علوم تحقیقات فارس، فارس، ایران. Kahin Shahanipoor کهین شاهانی پور shahanipur_k@yahoo.com 10031947532846005669 10031947532846005669 Yes Department of Biochemistry, Islamic Azad University, Falavarjan Branch, Isfahan, Iran. گروه بیوشیمی، دانشگاه آزاد اسلامی، واحد فلاورجان، اصفهان، ایران. Nemat al Razmi نعمت الله رزمی 10031947532846005670 10031947532846005670 No Department of Biochemistry, Islamic Azad University, Fars Science and Research Branch, Fars, Iran. گروه بیوشیمی، دانشگاه آزاد اسلامی، واحد علوم تحقیقات فارس، فارس، ایران.